Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, Vladimir J.N., Issaeva, Natalia, Shilov, Alexandre, Hultcrantz, Monica, Pugacheva, Elena, Chumakov, Peter, Bergman, Jan, Wiman, Klas G., Selivanova, Galina·2002·Nature Medicine
DOI 10.1038/nm0302-282

Cited by (1,000)

Items 701–800 of 1,000

  1. Characterizing the sphingomyelinase pathway triggered by PRIMA-1 derivatives in lung cancer cells with differing p53 status.
    Eroica Soans, Susan C. Evans, Cynthia M. Cipolla, Elroy Fernandes · 2014 · PubMed
  2. Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
    Xiuzhen Zhang, Tong Meng, Shuaishuai Cui, Ling Feng, Dongwu Liu, Qiuxiang Pang, Ping Wang · 2021 · Frontiers in Oncology
  3. Identification and structure–activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis
    N. Laxma Reddy, Jeanette R. Hill, Long Ye, PRABHAVATHI B. FERNANDES, David M. Stout · 2004 · Bioorganic & Medicinal Chemistry Letters
  4. Molecular targets in breast cancer: current status and future directions.
    Massimo Cristofanilli, Gabriel N. Hortobágyi · 2002 · Endocrine Related Cancer
  5. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague–Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study
    Indira Benakanakere, Cynthia L Besch-Williford, Mark R. Ellersieck, Salman M. Hyder · 2008 · Endocrine Related Cancer
  6. Cell Death Signaling in Malignancy
    Timothy Francis Burns, Wafik S. El‐Deiry · 2006 · Kluwer Academic Publishers eBooks
  7. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases
    Manabu Kawada, Ihomi Usami, Shun‐ichi Ohba, Tetsuya Someno, Jin Woo Kim, Yoichi Hayakawa, Kiyoshi Nose, Masaaki Ishizuka · 2002 · Biochemical and Biophysical Research Communications
  8. Anticancer therapeutic strategies for targeting mutant p53-Y220C
    Vitaly V. Chasov, Damir Davletshin, Elvina Gilyazova, Regina Mirgayazova, Anna A. Kudriaeva, Raniya Khadiullina, Youyong Yuan, Emil Bulatov · 2023 · Journal of Biomedical Research
  9. ABCB1 confers resistance to carboplatin by accumulating stem-like cells in the G2/M phase of the cell cycle in p53null ovarian cancer
    Danbi Lee, Hyun-Seok Jeong, Sun‐Young Hwang, Yu‐Gyeong Lee, Youn‐Jung Kang · 2025 · Cell Death Discovery
  10. Theranostic Protein Targeting ErbB2 for Bioluminescence Imaging and Therapy for Cancer
    Xiao-Jian Han, Ling-Fei Sun, Yuki Nishiyama, Bin Feng, Hiroyuki Michiue, Masaharu Seno, Hideki Matsui, Kazuhito Tomizawa · 2013 · PLoS ONE
  11. Targeted Therapy in Pediatric AML: An Evolving Landscape
    LaQuita M. Jones, Katherine Tarlock, Todd M. Cooper · 2021 · Pediatric Drugs
  12. The discovery of nongenotoxic activators of p53: Building on a cell-based high-throughput screen
    Anna R. McCarthy, Jonathan J. Hollick, Nicholas James Westwood · 2010 · Seminars in Cancer Biology
  13. E6 and E7 proteins from different beta-papillomaviruses types do not interfere in UVB-induced apoptosis of HaCaT keratinocytes
    Jean-Sébastien Guerrini, Véronique Bouvard, Evelyn Oswald, Ángel Alonso, Jean‐Luc Prétet, Massimo Tommasino, Christiane Mougin, François Aubin · 2010 · Experimental Dermatology
  14. The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells
    Anja Charlotte Lundgren Mortensen, Diana Spiegelberg, Christopher John Brown, David Philip Lane, Marika Nestor · 2019 · Frontiers in Oncology
  15. Restoration of conformation of mutant p53
    J.A. Green, M. Von Euler, Lars Abrahmsén · 2018 · Annals of Oncology
  16. Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development
    Shanshan Wang, Qian Hao, Jiajia Li, Yajie Chen, Hua Lu, Xiaohua Wu, Xiang Yu Zhou · 2020 · Genes & Diseases
  17. Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
    Douglas W. Brown, Perrin H. Beatty, John D. Lewis · 2022 · Cancers
  18. Delivery systems and molecular targets of mechanism-based therapies for GBM
    Surasak Phuphanich, Daniel Jay Brat, Jeffrey J. Olson · 2004 · Expert Review of Neurotherapeutics
  19. Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas
    Kanya Honoki, Toshifumi Tsujiuchi · 2013 · Expert Review of Anticancer Therapy
  20. Methods for screening tumors for p53 status and therapeutic exploitation
    Apollonia Tullo, Anna Maria D’Erchia, Elisabetta Sbisà · 2003 · Expert Review of Molecular Diagnostics
  21. Searching for novel therapeutics and targets: Insights from clinical trials
    Anirban Pradip Mitra, Richard J. Côté · 2007 · Urologic Oncology Seminars and Original Investigations
  22. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
    H. Moses Murdock, Vincent T. Ho, Jacqueline Suen Garcia · 2024 · Frontiers in Immunology
  23. Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics
    Nicole Santoro, Prassede Salutari, Mauro Di Ianni, Andrea Marra · 2024 · International Journal of Molecular Sciences
  24. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment
    Bénédicte Rousseau, Catherine Jacquot, Julie LE PALABE, Marine Malleter, Christophe Tomasoni, Tifenn Boutard, Vehary A. Sakanyan, Christos Roussakis · 2015 · Scientific Reports
  25. New Treatment Options for Older Patients with Acute Myeloid Leukemia
    Kapil Saxena, Marina Y Konopleva · 2021 · Current Treatment Options in Oncology
  26. Colletofragarone A2 and Colletoins A–C from a Fungus Colletotrichum sp. Decrease Mutant p53 Levels in Cells
    Yusaku Sadahiro, Yuki Hitora, Sachiko Tsukamoto · 2021 · Journal of Natural Products
  27. Therapeutic strategies for head and neck cancer based on p53 status
    Ichiro Ota, Noritomo Okamoto, Katsunari Yane, Akihisa Takahashi, Takashi Masui, Hiroshi Hosoi, Takeo Ohnishi · 2012 · Experimental and Therapeutic Medicine
  28. p53 R175H hydrophobic patch and H ‐bond reorganization observed by MD simulation
    Kelly M. Thayer, Taylor R. Quinn · 2015 · Biopolymers
  29. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals
    Saverio Candido, Stephen Lee Abrams, Linda S. Steelman, Kvin Lertpiriyapong, Alberto Maria Martelli, Lucio Cocco, Stefano Ratti, Matilde Y. Follo, Ramiro Mendonça Murata, Pedro Luiz Rosalen et al. · 2019 · Advances in Biological Regulation
  30. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia
    Jesus D. Gonzalez‐Lugo, Samarpana Chakraborty, Amit Verma, Aditi Shastri · 2020 · Seminars in Hematology
  31. Targeted therapies in the management of metastatic bladder cancer.
    Matteo Fassan, Edouard John Trabulsi, Leonard G. Gomella, Raffaele Baffa · 2007 · PubMed Central
  32. The Role of P53 Mutations As A Prognostic Factor and Therapeutic Target In Inflammatory Breast Cancer
    Charles H. Yang, Massimo Cristofanilli · 2006 · Future Oncology
  33. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc
    Elham Farhadi, Majid Safa, Ali Mohammad Sharifi, Davood Bashash · 2016 · Anti-Cancer Drugs
  34. Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding
    Husam A. Babikir, Rayhaneh Afjei, Ramasamy Paulmurugan, Tarik F. Massoud · 2018 · Cancer Treatment Reviews
  35. An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53
    Ibrahim Malami, Aliyu Idris Muhammad, Imaobong Christopher Etti, Peter Maitalata Waziri, Alhassan Muhammad Alhassan · 2017 · EXCLI journal
  36. Genetic Defects as Tumor Markers
    A. V. Lichtenstein, G. I. Potapova · 2003 · Molecular Biology
  37. Sunlight-induced three-component synthesis of α-aminoketones: a green and sustainable pathway through an EDA complex
    Jianwei Wang, Zhiqin Zhang, Chengrui Li, Miao Wang, Jiajing Tan, Hongguang Du, Ning Chen · 2024 · Organic Chemistry Frontiers
  38. Key genes altered in glioblastoma based on bioinformatics (Review)
    Marcelino Al Ghafari, Nour El Jaafari, Mariam Mouallem, Tala Maassarani, Mirvat El‐Sibai, Ralph Joseph Abi‐Habib · 2025 · Oncology Letters
  39. p53 in the Clinics
    Pierre L. Hainaut, Klas G. Wiman, Magali Olivier · 2012 · Springer eBooks
  40. The rare nonsense mutation in p53 triggers alternative splicing to produce a protein capable of inducing apoptosis
    Evgeny M. Makarov, Tatiana A. Shtam, Roman A. Kovalev, Rimma A. Pantina, E. Yu. Varfolomeeva, Michael V. Filatov · 2017 · PLoS ONE
  41. Virtual screening using covalent docking to find activators for G245S mutant p53
    Sara Ibrahim Omar, Marco Gaetano Lepre, Umberto Morbiducci, Marco A. Deriu, Jack A. Tuszyński · 2018 · PLoS ONE
  42. The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells
    Eric Jeffrey Devor, Brandon Schickling, Jace R. Lapierre, David Bender, Jesús González Bosquet, Kimberly Kay Leslie · 2021 · Pharmaceuticals
  43. Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
    Evgeny M. Kirilin, Timur I. Fetisov, Н. И. Моисеева, Ekaterina A. Lesovaya, Lidia A. Laletina, Leyla F. Makhmudova, Angelika E. Manikaylo, Liliya Y. Fomina, Denis A. Burov, Beniamin Yu. Bokhyan et al. · 2022 · Cancers
  44. Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage
    Cecilia Savorani, Valentina Manfé, Edyta Biskup, Robert Gniadecki · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
  45. Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration
    Connie A. Larsson, Sydney M. Moyer, Bin Liu, Keith A. Michel, Vinod Pant, Peirong Yang, Justin Wong, Adel K. El‐Naggar, Ralf Krahe, Guillermina Lozano · 2018 · Proceedings of the National Academy of Sciences
  46. RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity
    Johannes Ristau, Vincent van Hoef, Sylvain Peuget, Jiawei Zhu, Bo‐Jhih Guan, Shuo Liang, Maria Hatzoglou, Ivan Topisirović, Galina Selivanova, Ola Segnestam Larsson · 2019 · Cell Death and Disease
  47. Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia
    Frank N. van Leeuwen · 2020 · Haematologica
  48. DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development
    Rajasekaran Subbarayan, Dhasarathdev Srinivasan, Ranjith Balakrishnan, Ajeet Kumar, Salman Sadullah Usmani, Nityanand Srivastava · 2024 · International review of cytology
  49. Exploring the Potential of Plant-Based Nanotechnology in Cancer Immunotherapy: Benefits, Limitations, and Future Perspectives
    Ashish Kumar Pandey, Inès Karmous · 2024 · Biological Trace Element Research
  50. Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma
    Kazuchika Nishitsuji, Remi Mito, Midori Ikezaki, Hiromu Yano, Yukio Fujiwara, Eri Matsubara, Taro Nishikawa, Yoshito Ihara, Kenji Uchimura, Naoyuki Iwahashi et al. · 2024 · Cancer Science
  51. Asperolide A induces apoptosis and cell cycle arrest of human hepatoma cells with p53-Y220C mutant through p38 mediating phosphorylation of p53 (S33)
    Cuiting Lv, Aihua Lan, Xiao Fan, Caiguo Huang, Gong Yang · 2023 · Heliyon
  52. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas
    Cécile Le Page, Jacqueline W. Chung, Kurosh Rahimi, Martin Köbel, Diane Michele Provencher, Anne‐Marie Mes‐Masson · 2019 · Current Drug Targets
  53. PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells
    Zuzana Jašková, Šárka Pavlová, Jitka Malčíková, Yvona Brychtová, Martin Trbušek · 2019 · Leukemia Research
  54. Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis
    Chunwei Walter Lai, Cindy Xie, Jean‐Pierre Raufman, Guofeng Xie · 2022 · Cancers
  55. Transcriptomics and Proteomics Characterizing the Anticancer Mechanisms of Natural Rebeccamycin Analog Loonamycin in Breast Cancer Cells
    Xiao Sun, Zhan-Ying Lu, Zhenzhen Liang, Bowen Deng, Yuping Zhu, Jing Shi, Xiaoling Lü · 2022 · Molecules
  56. TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
    Ramy Rahmé, Thorsten Braun, James J. Manfredi, Pierre Fenaux · 2023 · Biomedicines
  57. Current Strategies in Cancer Gene Therapy
    Wolfgang Walther · 2016 · Recent results in cancer research/Recent Results in Cancer Research
  58. CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA
    Liz J. Hernández Borrero, Shengliang Zhang, Amriti R. Lulla, David T. Dicker, Wafik S. El‐Deiry · 2017 · Cell Cycle
  59. Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
    Phong Lu, Erica R. Vander Mause, Katherine E. Redd Bowman, Sarah M. Brown, Lisa Ahne, Carol S. Lim · 2019 · Journal of Ovarian Research
  60. Prima-1 and APR-246 in Cancer Therapy
    Pavlína Zatloukalová, Michaela Galoczová, Bořivoj Vojtěšek · 2018 · Klinicka onkologie
  61. Effect of new olivacine derivatives on p53 protein level
    Tomasz Gębarowski, Benita Wiatrak, Katarzyna Gębczak, Beata Tylińska, Kazimierz Gąsiorowski · 2020 · Pharmacological Reports
  62. p53: Balancing tumour suppression and implications for the clinic
    Yosef Buganim, Varda Rotter · 2009 · European Journal of Cancer
  63. Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
    Zhiyi Wang, Shijie Zhang, Irakoze Loïca Mélita, Yujun Zhao · 2025 · European Journal of Medicinal Chemistry
  64. Perspectives of gene combinations in phenotype presentation
    Shihori Tanabe · 2013 · World Journal of Stem Cells
  65. New developments in small molecules targeting p53 pathways in anticancer therapy
    Chit Fang Cheok, David Philip Lane · 2008 · Drug Development Research
  66. Targeted Sequencing of Sorted Esophageal Adenocarcinoma Cells Unveils Known and Novel Mutations in the Separated Subpopulations
    Federica Isidori, Isotta Bozzarelli, Luca Mastracci, Deborah Malvi, Marialuisa Lugaresi, Chiara Molinari, Henna K Söderström, Jari Veli Räsänen, Antonietta D’Errico, Roberto Fiocca et al. · 2020 · Clinical and Translational Gastroenterology
  67. Repurposing of neprilysin inhibitor ‘sacubitrilat’ as an anti-cancer drug by modulating epigenetic and apoptotic regulators
    Navanath Kumbhar, Snehal Nimal, Deeksha Patil, V. Florian Kaiser, Joachim Haupt, Rajesh Nivarti Gacche · 2023 · Scientific Reports
  68. Single chain antibody against the common epitope of mutant p53 restores wild‐type activity to mutant p53 protein
    Sara Orgad, Naomi Goldfinger, Gerald Cohen, Varda Rotter, Beka Solomon · 2005 · FEBS Letters
  69. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein
    György Stuber, Emilie Flaberg, Gabor Petrányi, Rita Hutyra-Gram Ötvös, Nina Rökaeus, Elena Kashuba, Klas G. Wiman, George Klein, László Székely · 2009 · Molecular Cancer
  70. The Effect of Adenovirus-Mediated Gene Expression of FHIT in Small Cell Lung Cancer Cells
    Roza Zandi, Kai Xu, Hans Skovgaard Poulsen, Jack A. Roth, Lin Ji · 2011 · Cancer Investigation
  71. The Life Cycle of P53: A Key Target in Drug Development
    Lee E. Finlan, Ted R. Hupp · 2006 · Springer eBooks
  72. Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties
    Sara Ibrahim Omar, Jack A. Tuszyński · 2014 · Chemical Biology & Drug Design
  73. MDM4 expression in fibrolamellar hepatocellular carcinoma
    Anju Karki, Juan Putra, Stephanie M. Kim, Michael P. LaQuaglia, Antonio R. Pérez‐Atayde, Ghazaleh Sadri‐Vakili, Khashayar Vakili · 2019 · Oncology Reports
  74. p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules
    Ananthan Sadagopan, Nicholas Garaffo, Heng-Jui Chang, Stuart L. Schreiber, Matthew M. Meyerson, William J. Gibson · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  75. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53
    Stephen Lee Abrams, Shaw M. Akula, Alberto Maria Martelli, Lucio Cocco, Stefano Ratti, Massimo Libra, Saverio Candido, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak et al. · 2021 · Advances in Biological Regulation
  76. Natural products that target p53 for cancer therapy
    Sachiko Tsukamoto · 2025 · Journal of Natural Medicines
  77. Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells
    Masashi Idogawa, Tomoko Ohashi, Jun Sugisaka, Yasushi Sasaki, Hiromu Suzuki, Takashi Tokino · 2014 · Oncotarget
  78. The General Information of the Tumor Suppressor Gene p53 and the Protein p53
    Zheying Sun · 2015 · Journal of Cancer Prevention & Current Research
  79. MPK-09, a Small Molecule Inspired from Bioactive Styryllactone Restores the Wild-Type Function of Mutant p53
    Prashant K. Metri, Sarwat Naz, Paturu Kondaiah, Kavirayani R. Prasad · 2013 · ACS Chemical Biology
  80. Apoptosis in Cancer
    Zahid Hussain Siddik · 2014 · Elsevier eBooks
  81. p53 in Head and Neck Squamous Cell Carcinoma
    Ramez H. W. Philips, Quintin Pan · 2017 · Springer eBooks
  82. Targeting p53 as a Promising Therapeutic Option for Cancer By Re-Activating the Wt Or Mutant p53’s Tumor Suppression
    Józefa Węsierska‐Gądek · 2018 · Future Medicinal Chemistry
  83. Growth inhibitory role of the p53 activator SCH�529074 in non‑small cell lung cancer cells expressing mutant�p53
    Miljana Nenkov, Yunxia Ma, Daniela Haase, Zhong‐Wei Zhou, Yong Li, Iver Petersen, Guanghua Lu, Yuan Chen · 2020 · Oncology Reports
  84. Suberoylanilide hydroxamic acid enhances the radiosensitivity of lung cancer cells through acetylated wild-type and mutant p53-dependent modulation of mitochondrial apoptosis
    Kan Wu, Xueqin Chen, Xufeng Chen, Shirong Zhang, Yasi Xu, Bing Xia, Shenglin Ma · 2021 · Journal of International Medical Research
  85. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions
    Abhishek Maiti, Naval Guastad Daver · 2022 · Journal of Clinical Oncology
  86. Anti-inflammatory effects of PRIMA-1MET (mutant p53 reactivator) induced by inhibition of nuclear factor-κB on rheumatoid arthritis fibroblast-like synoviocytes
    Mehrnoosh Adib, Mahdi Taghadosi, Mohammad Naghi Tahmasebi, Arash Sharafat Vaziri, Ahmadreza Jamshidi, Mahdi Mahmoudi, Elham Farhadi · 2022 · Inflammopharmacology
  87. Telomere maintenance mechanisms in neuroblastoma: New insights and translational implications
    Lisa Werr, Carolina Rosswog, Christoph Bartenhagen, Sally L. George, Matthias Fischer · 2024 · EJC Paediatric Oncology
  88. Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models
    Toby James Phesse, Victoria Marsh Durban, Owen James Sansom · 2017 · Carcinogenesis
  89. Tumor Suppressor Genes in Myeloid Differentiation and Leukemogenesis
    Christian Britschgi, Martin F. Fey · 2009 · Future Oncology
  90. Identification by high-throughput in silico screening of radio-protecting compounds targeting the DNA-binding domain of the tumor suppressor p53.
    Tolga Eichhorn, Corinna Hiller, Kerstin Hirschfelder, Martin Frank, R. Luise Krauth‐Siegel, Rolf Müller, Rolf Mertens, Thomas Efferth · 2013 · PubMed
  91. Apoptosis in health, disease, and therapy: overview and methodology
    Eric Charles LaCasse, Martin Holčı́k, Robert G. Korneluk, Alex MacKenzie · 2005 · Cambridge University Press eBooks
  92. The hallmarks of pancreatic cancer
    Laura E. Kane, David Hackett, Rebecca G. Lyons, Barbara Mary Ryan, Stephen G. Maher · 2026 · Cancer Letters
  93. Colletofragarone A2 Inhibits Cancer Cell Growth In Vivo and Leads to the Degradation and Aggregation of Mutant p53
    Yusaku Sadahiro, Yuki Hitora, Ichiro Kimura, Natsuko HitoraーImamura, Risako Onodera, Keiichi Motoyama, Sachiko Tsukamoto · 2022 · Chemical Research in Toxicology
  94. A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer
    Bohao Zhang, Haozhe Zhang, Yanru Qin · 2025 · Frontiers in Bioscience-Landmark
  95. Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
    Julia V. Milne, Bonnie Z. Zhang, Kenji Mark Fujihara, Swati Dawar, Wayne Allen Phillips, Nicholas James Clemons · 2021 · Scientific Reports
  96. Structural Basis of Mutation-Dependent p53 Tetramerization Deficiency
    Marta Rigoli, Giovanni Spagnolli, Giulia Lorengo, Paola Monti, Raffaello Potestio, Emiliano Biasini, Alberto Inga · 2022 · International Journal of Molecular Sciences
  97. SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes
    Brandon J. Aubrey, Andrew Mark Brunner · 2022 · Clinical Lymphoma Myeloma & Leukemia
  98. Major genomic mutations driving hepatocellular carcinoma
    Ran Chen, Moubin Lin, Daming Gao · 2023 · Genome Instability & Disease
  99. p53: Regular or super?
    Martine F. Roussel · 2002 · Cancer Cell
  100. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects
    Konstantinos G. Drosopoulos, Alexander Pintzas · 2007 · Expert Opinion on Therapeutic Targets